JCT  Vol.5 No.8 , July 2014
Gastrointestinal Stromal Tumors in the 21st Century

Gastrointestinal stromal tumours (GISTs) are rare mesenchymal lesions accounting for only 0.2% of all gastrointestinal neoplasms. These tumors arise from the interstitial cells of Cajal, with mutations described in proto-oncogenes such as KIT, PDGFRA, DOG-1, and SDH. The majority of these lesions are asymptomatic, thus the true incidence remains unknown. While patients typically undergo initial endoscopy, CT scan and/or MRI, findings are often nonspecific and require a biopsy to identify the tumor. As such, immunohistochemical evaluation is the gold-standard for the accurate diagnosis of GIST. Though surgical excision remains the gold-standard for curative management, the discovery of imatinib, a tyrosine kinase inhibitor (TKI), has revolutionized the treatment of GIST in the 21st century as a “prototype” of molecular targeted therapy for solid tumors. Risk assessment for recurrence divides these tumors into low and high-risk categories. In the latter, a role for adjuvant therapy with TKI confers a significantly better prognosis than previously observed. However, secondary mutations conferring drug resistance remain an ongoing challenge for management, as few alternative treatment options are available for patients intolerant/refractory to TKI therapy. In this review, we summarize the epidemiology, molecular pathogenesis, clinical presentation, diagnosis, pathology features, management options, and prognostic features of GISTs.

Cite this paper
Kanthan, R. , Senger, J. , Ahmed, S. and Kanthan, S. (2014) Gastrointestinal Stromal Tumors in the 21st Century. Journal of Cancer Therapy, 5, 769-796. doi: 10.4236/jct.2014.58086.
[1]   Rammohan, A., Sathyanesan, J., Rajendran, K., Pitchaimuthu, A., Perumal, S.K., Srinivasan, U., Ramasamy, R., Palaniappan, R. and Govindan, M. (2013) A Gist of Gastrointestinal Stromal Tumors: A Review. World Journal of Gastrointestinal Oncology, 5, 102-112.

[2]   Chaudhry, U.I. and Dematteo, R.P. (2011) Advances in the Surgical Management of Gastrointestinal Stromal Tumor. Advances in Surgery, 45, 197-209. http://dx.doi.org/10.1016/j.yasu.2011.03.018

[3]   Janeway, K.A. and Weldon, C.B. (2012) Pediatric Gastrointestinal Stromal Tumor. Seminars in Pediatric Surgery, 21, 31-43. http://dx.doi.org/10.1053/j.sempedsurg.2011.10.003

[4]   Beham, A.W., Schaefer, I.M., SchüLer, P., Cameron, S. and Ghadimi, B.M. (2012) Gastrointestinal Stromal Tumors. International Journal of Colorectal Disease, 27, 689-700.

[5]   Kapoor, R., Khosla, D., Kumar, P., Kumar, N. and Bera, A. (2013) Five-Year Follow up of Patients with Gastrointestinal Stromal Tumor: Recurrence-Free Survival by Risk Group. Asia-Pacific Journal of Clinical Oncology, 9, 40-46. http://dx.doi.org/10.1111/j.1743-7563.2011.01494.x

[6]   Sioulas, A.D., Vasilatou, D., Pappa, V., Dimitriadis, G. and Triantafyllou, K. (2013) Epigenetics in Gastrointestinal Stromal Tumors: Clinical Implications and Potential Therapeutic Perspectives. Digestive Diseases and Sciences, 58, 3094-3102. http://dx.doi.org/10.1007/s10620-013-2785-8

[7]   Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., et al. (1998) Gain-of-Function Mutations of C-Kit in Human Gastrointestinal Stromal Tumors. Science, 279, 577-580.

[8]   Lamba, G., Gupta, R., Lee, B., Ambrale, S. and Liu, D. (2012) Current Management and Prognostic Features for Gastrointestinal Stromal Tumor (GIST). Experimental Hematology & Oncology, 1, 14.

[9]   Atmatzidis, S., Chatzimavroudis, G., Ananiadis, A., Kapoulas, S. and Atmatzidis, K. (2013) Giant GIST of the Small Intestine in a Young Man. Journal of Gastrointestinal Surgery, 17, 1536-1537.

[10]   Bhalgami, R., Manish, K., Patil, P., Mehta, S. and Mohandas, K.M. (2013) Clinicopathological Study of 113 Gastrointestinal Stromal Tumors. Indian Journal of Gastroenterology, 32, 22-27.

[11]   Miettinen, M. and Lasota, J. (2013) Gastrointestinal Stromal Tumors. Gastroenterology Clinics of North America, 42, 399-415. http://dx.doi.org/10.1016/j.gtc.2013.01.001

[12]   Shaheen, S. and Guddati, A. (2013) Gastrointestinal Stromal Tumor: A Rare Abdominal Tumor. Case Reports in Oncology, 6, 148-153. http://dx.doi.org/10.1159/000350061

[13]   Eisenberg, B.L. and Pipas, J.M. (2012) Gastrointestinal Stromal Tumor—Background, Pathology, Treatment. Hematology/Oncology Clinics of North America, 26, 1239-1259.

[14]   Nakayama, Y., Kadowaki, K., Higure, A., Hisaoka, M. and Yamaguchi, K. (2013) Synchronous Sporadic Gastrointestinal Stromal Tumors in the Stomach and Jejunum: Report of a Case. Case Reports in Gastroenterology, 7, 69-74. http://dx.doi.org/10.1159/000348754

[15]   Skandalos, I.K., Hotzoglou, N.F., Matsi, K.C., Pitta, X.A. and Kamas, A.I. (2013) Giant Extra Gastrointestinal Stromal Tumor of the Lesser Omentum Obscuring the Diagnosis of a Choloperitoneum. International Journal of Surgery Case Reports, 4, 818-821.

[16]   Louis, A.R., Singh, S., Gupta, S.K. and Sharma, A. (2013) Primary GIST of the Liver Masquerading as Primary Intra-Abdominal Tumour: A Rare Extra-Gastrointestinal Stromal Tumour (EGIST) of the Liver. Journal of Gastrointestinal Cancer.

[17]   Nakajima, T., Ushijima, T., Kihara, A., Murata, K., Sugiyama, T., Tsuneyama, K., Imura, J., Fukushima, J. and Horiuchi, H. (2012) A Gastrointestinal Stromal Tumor of the Stomach Demonstrating A Stepwise Progression From Low- to High-Grade Malignancy. Case Reports in Gastrointestinal Medicine, 2012, Article ID: 606832.

[18]   Seshadri, R.A., Singh, S.S. and Ratnagiri, R. (2012) Synchronous Jejunal Gastrointestinal Stromal Tumor and Primary Adenocarcinoma of the Colon. Indian Journal of Surgery, 74, 196-198.

[19]   Cai, R., Ren, G. and Wang, D.B. (2013) Synchronous Adenocarcinoma and Gastrointestinal Stromal Tumors in the Stomach. World Journal of Gastroenterology, 19, 3117-3123.

[20]   Joensuu, H., Hohenberger, P. and Corless, C.L. (2013) Gastrointestinal Stromal Tumour. Lancet, 382, 973-983. http://dx.doi.org/10.1016/S0140-6736(13)60106-3

[21]   Wong, R.J., Longacre, T.A., Poultsides, G., Park, W. and Rothenberg, M.E. (2013) Gastrointestinal Stromal Tumor: An Unusual Cause of Gastrointestinal Bleeding. Digestive Diseases and Sciences, 58, 3112-3116. http://dx.doi.org/10.1007/s10620-013-2678-x

[22]   Patil, D.T. and Rubin, B.P. (2011) Gastrointestinal Stromal Tumor: Advances in Diagnosis and Management. Archives of Pathology & Laboratory Medicine, 135, 1298-1310.

[23]   Asija, A.P., Mejia, A.V., Prestipino, A. and Pillai, M.V. (2013) Gastrointestinal Stromal Tumors: A Review. American Journal of Therapeutics. http://dx.doi.org/10.1097/MJT.0b013e3182a1be76

[24]   Tan, C.B., Zhi, W., Shahzad, G. and Mustacchia, P. (2012) Gastrointestinal Stromal Tumors: A Review of Case Reports, Diagnosis, Treatment, and Future Directions. ISRN Gastroenterology, 2012, Article ID: 595968.

[25]   Mikami, T., Nemoto, Y., Numata, Y., Hana, K., Nakada, N., Ichinoe, M., Murakumo, Y. and Okayasu, I. (2013) Small Gastrointestinal Stromal Tumor in the Stomach: Identification of Precursor for Clinical Gastrointestinal Stromal Tumor Using c-Kit and α-Smooth Muscle Actin Expression. Human Pathology, 44, 2628-2635. http://dx.doi.org/10.1016/j.humpath.2013.07.020

[26]   Barnett, C.M., Corless, C.L. and Heinrich, M.C. (2013) Gastrointestinal Stromal Tumors: Molecular Markers and Genetic Subtypes. Hematology/Oncology Clinics of North America, 27, 871-888.

[27]   Machairiotis, N., Kougioumtzi, I., Zarogoulidis, P., Stylianaki, A., Tsimogiannis, K. and Katsikogiannis, N. (2013) Gastrointestinal Stromal Tumor Mesenchymal Neoplasms: The Offspring That Choose the Wrong Path. Journal of Multidisciplinary Healthcare, 6, 127-131.

[28]   Corless, C.L., Schroeder, A., Griffith, D., Town, A., Mcgreevey, L., Harrell, P., Shiraga, S., Bainbridge, T., Morich, J. and Heinrich, M.C. (2005) PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and in Vitro Sensitivity to Imatinib. Journal of Clinical Oncology, 23, 5357-5364.

[29]   Ricci, R., Dei Tos, A.P. and Rindi, G. (2013) Gistogram: A Graphic Presentation of the Growing GIST Complexity. Virchows Archiv, 463, 481-487. http://dx.doi.org/10.1007/s00428-013-1467-4

[30]   Duffaud, F., Salas, S. and Huynh, T. (2010) Recent Advances in the Management of Gastrointestinal Stromal Tumors. F1000 Medicine Reports, 2, 36.

[31]   O’Brien, K.M., Orlow, I., Antonescu, C.R., Ballman, K., Mccall, L., Dematteo, R. and Engel, L.S. (2013) Gastrointestinal Stromal Tumors, Somatic Mutations and Candidate Genetic Risk Variants. PLoS ONE, 8, Article ID: e62119. http://dx.doi.org/10.1371/journal.pone.0062119

[32]   Silva, A.G., Lisboa, B.C.G., Achatz, M.I.W., Carraro, D.M., Da Cunha, I.W., Pearson, P.I., et al. (2013) Germline BAX Deletion in a Patient with Melanoma and Gastrointestinal Stromal Tumor. American Journal of Gastroenterology, 108, 1372-1375. http://dx.doi.org/10.1038/ajg.2013.176

[33]   Nannini, M., Pantaleo, M.A. and Biasco, G. (2013) Role of Molecular Analysis in the Adjuvant Treatment of Gastrointestinal Stromal Tumours: Is It Time to Define It. World Journal of Gastroenterology, 19, 2583-2586. http://dx.doi.org/10.3748/wjg.v19.i16.2583

[34]   Miettinen, M. and Lasota, J. (2014) Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumors (Gists)—A Review. The International Journal of Biochemistry & Cell Biology, in Press.

[35]   Gits, C.M.M., Van Kujik, P.F., Jonkers, M.B.E., Boersma, A.W.M., Van Ijcken, W.F., Wozniak, A., et al. (2013) MiR-17-92 and MiR-221/222 Cluster Members Target KIT and ETV1 in Human Gastrointestinal Stromal Tumours. British Journal of Cancer, 109, 1625-1635. http://dx.doi.org/10.1038/bjc.2013.483

[36]   Ling, J., Lamsen, M., Coron, R., Deliana, D., Siddiqui, S., Rangraj, M. and Jesmajian, S. (2013) Recurrent Lower Gastrointestinal Bleeding: Ileal GIST Diagnosed by Video Capsule Endoscopy—A Case Report and Literature Review. Case Reports in Gastrointestinal Medicine, 2013, Article ID: 285457.

[37]   Mouaqit, Q., Chbani, L., Maazaz, K., Amarti, A., Taleb, K.A. and Oussaden, A. (2013) A Large Gastrointestinal Stromal Tumor of the Duodenum Treated by Partial Duodenectomy with Roux-en-Y Duodenojejunostomy: A Case Report. Journal of Medical Case Reports, 7, 184.

[38]   Ratan, S.K., Goet, G., Sobti, P., Khurana, N., Mathur, M., Sinha, S.K. and Aggarwal, S.K. (2013) Colonic Gastrointestinal Stromal Tumour Presenting as Intussuception. APSP Journal of Case Reports, 4, 19.

[39]   Kong, S.H. and Yang, H.K. (2013) Surgical Treatment of Gastric Gastrointestinal Stromal Tumor. Journal of Gastric Cancer, 13, 3-18. http://dx.doi.org/10.5230/jgc.2013.13.1.3

[40]   Foo, W.C., Liegl-Atzwanger, B. and Lazar, A.J. (2012) Pathology of Gastrointestinal Stromal Tumors. Clinical Medicine Insights. Pathology, 5, 23-33.

[41]   Bachet, J.B., Landi, B., Laurent-Puig, P., Italiano, A., Le Cesne, A., Levy, P., et al. (2013) Diagnosis, Prognosis and Treatment of Patients with Gastrointestinal Stromal Tumour (GIST) and Germline Mutation of KIT Exon 13. European Journal of Cancer, 49, 2531-2541.

[42]   Belinsky, M.G., Rink, L. and Von Mehren, M. (2013) Succinate Dehydrogenase Deficiency in Pediatric and Adult Gastrointestinal Stromal Tumors. Frontiers in Oncology, 3, 117.

[43]   O’Regan, K.N., Shinagare, A.B., Saboo, S.S., Ramaiya, N.H., Jagannathan, J.P. and Tirumani, S.H. (2013) Gastrointestinal Stromal Tumors (GIST): Lesser Known Facts. Clinical Imaging, 37, 821-829.

[44]   Sawalhi, S., Al-Harbi, K., Raghib, Z., Abdelrahman, A.I. and Al-Hujaily, A. (2013) Behavior of Advanced Gastrointestinal Stromal Tumor in a Patient with Von-Recklinghausen Disease: Case Report. World Journal of Clinical Oncology, 4, 70-74. http://dx.doi.org/10.5306/wjco.v4.i3.70

[45]   Sicklick, J.K. and Lopez, N.E. (2013) Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors. Journal of Gastrointestinal Surgery, 17, 1997-2006.

[46]   Grover, S., Ashley, S.W. and Raut, C.P. (2012) Small Intestine Gastrointestinal Stromal Tumors. Current Opinion in Gastroenterology, 28, 113-123.

[47]   Mullady, D.K. and Tan, B.R. (2013) A Multidisciplinary Approach to the Diagnosis and Treatment of Gastrointestinal Stromal Tumor. Journal of Clinical Gastroenterology, 47, 578-585.

[48]   Khati, N.J. and Voci, S.L. (2013) Gastrointestinal Stromal Tumor of the Stomach. Ultrasound Quarterly, 29, 221-222. http://dx.doi.org/10.1097/RUQ.0b013e3182a0af60

[49]   De Vogelaere, K., Meert, V., Vandenbroucke, F., Delvaux, G. and Hoorens, A. (2012) Unusual Appearance of a Pendunculated Gastric Tumor: Always Think of GIST. Case Reports in Surgery, 2012, Article ID: 815941.

[50]   Werewka-Maczuga, A., Osinski, T., Chrzan, R., Buczek, M. and Urbanik, A. (2011) Characteristics of Computed Tomography Imaging of Gastrointestinal Stromal Tumor (GIST) and Related Diagnostic Problems. Polish Journal of Radiology, 76, 38-48.

[51]   Metildi, C.A., Tang, C.M., Kaushal, S., Leonard, S.Y., Magistri, P., Cao, H.S.T., Hoffman, R.M., Bouvet, M. and Sicklick, J.K. (2013) In Vivo Fluorescence Imaging of Gastrointestinal Stromal Tumors Using Fluorophore-Conjugated Anti-KIT Antibody. Annals of Surgical Oncology, 20, 693-700.

[52]   Todaro, P., Crinò, S.F., Pallio, S., Fazzari, C., Consolo, P. and Tuccari, G. (2013) Gastrointestinal Stromal Tumours of the Stomach: Cytological and Immunocytochemical Diagnostic Features of Two Cases Diagnosed by Endoscopic Ultrasound-Guided Fine Needle Aspiration. Oncology Letters, 5, 1862-1866.

[53]   Akahoshi, K. and Oya, M. (2010) Gastrointestinal Stromal Tumor of the Stomach: How to Manage? World Journal of Gastrointestinal Endoscopy, 2, 271-277. http://dx.doi.org/10.4253/wjge.v2.i8.271

[54]   Mushtaq, S., Mamoon, N., Hassan, U., Iqbal, M., Khadim, M.T. and Sarfraz, T. (2009) Gastrointestinal Stromal Tumors—A Morphological and Immunohistochemical Study. Journal of Gastrointestinal Cancer, 40, 109-114. http://dx.doi.org/10.1007/s12029-009-9108-5

[55]   Shaw, A., Jeffery, J., Dias, L. and Nazir, S. (2013) Duodenal Wedge Resection for Large Gastrointestinal Stromal Tumour Presenting with Life-Threatening Haemorrhage. Case Reports in Gastrointestinal Medicine, 2013, Article ID: 562642.

[56]   Miettinen, M. and Lasota, J. (2011) Histopathology of Gastrointestinal Stromal Tumor. Journal of Surgical Oncology, 104, 865-873. http://dx.doi.org/10.1002/jso.21945

[57]   Kaur, G., Manucha, V. and Verma, K. (2010) Gastrointestinal Stromal Tumors: Cytomorphologic Spectrum in Fine Needle Aspiration Smears. Indian Journal of Pathology & Microbiology, 53, 271-275.

[58]   Agaimy, A., Otto, C., Braun, A., Geddert, H., Schaefer, I.M. and Haller, F. (2013) Value of Epithelioid Morphology and PDGFRA Imunostaining Pattern for Prediction of PDGFRA Mutated Genotype in Gastrointestinal Stromal Tumors (Gists). International Journal of Clinical and Experimental Pathology, 6, 1839-1846.

[59]   Cavaniglia, D., Petrucciani, N., Lorenzon, L., Caterino, S. and Cavallini, M. (2012) Partial Duodenectomy with End-to-End Anastomosis for Duodenal Gastrointestinal Stromal Tumor. American Surgeon, 78, E273-E275.

[60]   Wang, C., Jin, M.S., Zou, Y.V., Gao, J.N., Li, X.B., Peng, F., et al. (2013) Diagnostic Significance of DOG-1 and PKC-Delta Expression and C-Kit/PDGFRA Mutations in Gastrointestinal Stromal Tumours. Scandinavian Journal of Gastroenterology, 48, 1055-1065.

[61]   Kara, T., Serinsoz, E., Arpaci, R.B., Gubur, O., Orekici, G., Ata, A., Colak, T. and Arican, A. (2013) Contribution of DOG1 Expression to the Diagnosis of Gastrointestinal Stromal Tumors. Pathology-Research and Practice, 209, 413-417. http://dx.doi.org/10.1016/j.prp.2013.04.005

[62]   Schwameis, K., Fochtmann, A., Schwameis, M., Asari, R., Schur, S., Kostler, W., et al. (2013) Surgical Treatment of GIST—An Institutional Experience. International Journal of Surgery, 11, 801-806. http://dx.doi.org/10.1016/j.ijsu.2013.08.016

[63]   Peparini, N. and Chirletti, P. (2013) Tumor Rupture during Surgery for Gastrointestinal Stromal Tumors: Pay Attention! World Journal of Gastroenterology, 19, 2009-2010.

[64]   Koh, Y.X., Chok, A.Y., Zheng, H.L., Tan, C.S., Chow, P.K., Wong, W.K. and Goh, B.K. (2013) A Systemic Review and Meta-Analysis Comparing Laparoscopic versus Open Gastric Resections for Gastrointestinal Stromal Tumors of the Stomach. Annals of Surgical Oncology, 20, 3549-3560.

[65]   Valle, M., Federici, O., Carboni, F., Carpano, S., Benedetti, M. and Garofalo, A. (2013) Gastrointestinal Stromal Tumors of the Stomach: The Role of Laparoscopic Resection. Single-Centre Experience of 38 Cases. Surgical Endoscopy, 28, 1040-1047.

[66]   Kiyozaki, H., Saito, M., Chiba, H., Takata, O. and Rikiyama, T. (2013) Laparoscopic Wedge Resection of the Stomach for Gastroin Testinal Stromal Tumor (GIST): Non-Touch Lesion Lifting Method. Gastric Cancer, 17, 337-340.

[67]   Lee, P.C., Lai, P.S., Yang, C.Y., Chen, C.N., Lai, R. and Lin, M.T. (2013) A Gasless Laparoscopic Technique of Wide Excision for Gastric Gastrointestinal Stromal Tumor versus Open Method. World Journal of Surgical Oncology, 11, 44. http://dx.doi.org/10.1186/1477-7819-11-44

[68]   De Vogelaere, K., Van De Winkel, N., Simoens, C. and Delvaux, G. (2013) Intragastric SILS for GIST, A New Challenge in Oncologic Surgery: First Experiences. Anticancer Research, 33, 3359-3364.

[69]   Liang, J.W., Zheng, Z.C., Zhang, J.J., Zhang, T., Zhao, Y., Yang, W. and Liu, Y.Q. (2013) Laparoscopic versus Open Gastric Resections for Gastric Gastrointestinal Stromal Tumors: A Meta-Analysis. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques, 23, 378-387.

[70]   Hoeppner, J., Kulemann, B., Marjanovic, G., Bronsert, P. and Hopt, U.T. (2013) Limited Resection for Duodenal Gastrointestinal Stromal Tumors: Surgical Management and Clinical Outcome. World Journal of Gastrointestinal Surgery, 5, 16-21. http://dx.doi.org/10.4240/wjgs.v5.i2.16

[71]   Zhou, B., Zhang, M., Wu, J., Yan, S., Zhou, J. and Zheng, S.S. (2013) Pancreaticoduodenectomy versus Local Resection in the Treatment of Gastrointestinal Stromal Tumors of the Duodenum. World Journal of Surgical Oncology, 11, 196. http://dx.doi.org/10.1186/1477-7819-11-196

[72]   Patil, M., Sheth, K.A., Adarsh, C.K., Manjunath, S. and Devarbhavi, H. (2014) Duodenal Gastrointestinal Stromal Tumor Presenting as Massive Gastrointestinal Bleed. Indian Journal of Gastroenterology, 33, 192-194.

[73]   Yamashita, S., Sakamoto, Y., Saiura, A., Yamamoto, J., Kosuge, T., Aoki, T., Sugawara, Y., Hasegawa, K. and Kokudo, N. (2014) Pancreas-Sparing Duodenectomy for Gastrointestinal Stromal Tumor. American Journal of Surgery, 207, 578-583.

[74]   Colombo, C., Ronellenfitsch, U., Yuxin, Z., Rutkowski, P., Miceli, R., Bylina, E., Hohenberger, P., Raut, C.P. and Gronchi, A. (2012) Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-Center Study. Annals of Surgical Oncology, 19, 3361-3367. http://dx.doi.org/10.1245/s10434-012-2559-0

[75]   Amato, A. (2010) Colorectal Gastrointestinal Stromal Tumor. Techniques in Coloproctology, 14, S91-S95. http://dx.doi.org/10.1007/s10151-010-0631-y

[76]   Singhal, S., Singhal, A., Tugnait, R., Varghese, V., Tiwari, B., Arora, P.K., et al. (2013) Anorectal Gastrointestinal Stromal Tumor: A Case Report and Literature Review. Case Reports in Gastrointestinal Medicine, 2013, Article ID: 934875.

[77]   Van Der Zwan, S.M. and De Matteo, R.P. (2005) Gastrointestinal Stromal Tumour: 5 Years Later. Cancer, 104, 1781-1788. http://dx.doi.org/10.1002/cncr.21419

[78]   Joensuu, H., Vehtari, A., Riihimaki, J., et al. (2012) Risk of Recurrence of Gastrointestinal Stromal Tumour after Surgery: An Analysis of Pooled Population-Based Cohorts. Lancet Oncology, 13, 265-274. http://dx.doi.org/10.1016/S1470-2045(11)70299-6

[79]   Joensuu, H. (2013) Gastrointestinal Stromal Tumors. Risk Assessment and Adjuvant Therapy. Hematology/Oncology Clinics of North America, 27, 889-904.

[80]   Trabelsi, A., Yacoub-Abid, L.B., Mtimet, A., Abdelkrim, S.B., Hammedi, F., Ali, A.B. and Mokni, M. (2009) Gastrointestinal Stromal Tumor of the Pancreas. A Case Report and Review of the Literature. North American Journal of Medical Sciences, 1, 324-327.

[81]   Maki, R.G. (2012) The Rule of Fives, a Simple Way to Stratify Risk for Primary Gastrointestinal Stromal Tumors (GIST). Clinical Sarcoma Research, 2, 21. http://dx.doi.org/10.1186/2045-3329-2-21

[82]   Raut, C.P. and Gronchi, A. (2013) Cytoreductive Surgery in Advanced GIST: Timing Is Everything. Annals of Surgical Oncology, 20, 4059-4060. http://dx.doi.org/10.1245/s10434-013-3281-2

[83]   Joensuu, H., Roberts, P.J., Sarlomo-Rikala, M., Andersson, L.C., Tervahartiala, P., Tuveson, D., et al. (2001) Effect of the Tyrosine Kinase Inhibitor STI571 in A Patient with A Metastatic Gastrointestinal Stromal Tumor. New England Journal of Medicine, 344, 1052-1056.

[84]   Van Oosterom, A.T., Judson, I.R., Verweij, J., et al., European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma (2002) Update of Phase I Study of Imatinib (STI571) in Advanced Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors: A Report of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer, 38, S83-S87. http://dx.doi.org/10.1016/S0959-8049(02)80608-6

[85]   Demetri, G.D., Von Mehren, M., Blanke, C.D., et al. (2002) Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. New England Journal of Medicine, 347, 472-480.

[86]   Verweij, J., Casali, P.G., Zalcberg, J., LeCesne, A., Reichardt, P., et al. (2004) Progression-Free Survival in Gastrointestinal Stromal Tumours with High-Dose Imatinib: Randomised Trial. The Lancet, 364, 1127-1134. http://dx.doi.org/10.1016/S0140-6736(04)17098-0

[87]   Doi, T., Nishida, T., Hirota, S., Sugiyama, T., Yamao, K., Koseki, M., Okamura, T., Shirao, K. and Ohtsu, A. (2004) Phase II Clinical Study of STI571 in Japanese (Jpn) Patients (Pts) with Malignant Gastrointestinal Stromal Tumors (GIST): Results of the B 1201 Study. Journal of Clinical Oncology, 22, 4078.

[88]   Von Mehren, M., Heinrich, M.C., Joensuu, H., Blanke, C.D., Wehrle, E. and Demetri, G.D. (2011) Follow-Up Results after 9 Years (Yrs) of the Ongoing, Phase II B2222 Trial of Imatinib Mesylate (IM) in Patients (Pts) with Metastatic or Unresectable KIT+ Gastrointestinal Stromal Tumors (GIST). (Abstract 10016). Journal of Clinical Oncology, 29.

[89]   Blanke, C.D., Demetri, G.D., Von Mehren, M., Heinrich, M.C., Eisenberg, B., Fletcher, J.A., et al. (2008) Long-Term Results from a Randomized Phase II Trial of Standardversus Higher-Dose Imatinib Mesylate for Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT. Journal of Clinical Oncology, 26, 620-625. http://dx.doi.org/10.1200/JCO.2007.13.4403

[90]   Blanke, C.D., Rankin, C., Demetri, G.D., Ryan, C.W., von Mehren, M., Benjamin, R.S., et al. (2008) Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate at Two Dose Levels in Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. Journal of Clinical Oncology, 26, 626-632.

[91]   Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients. Journal of Clinical Oncology, 28, 1247-1253.

[92]   Blay, J.Y., Le Cesne, A., Ray-Coquard, I., Bui, B., Duffaud, F., Delbaldo, C., et al. (2007) Prospective Multicentric Randomized Phase III Study of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors Comparing Interruption versus Continuation of Treatment beyond 1 Year: The French Sarcoma Group. Journal of Clinical Oncology, 25, 1107-1113. http://dx.doi.org/10.1200/JCO.2006.09.0183

[93]   Linch, M., Claus, J. and Benson, C. (2013) Update on Imatinib for Gastrointestinal Stromal Tumors: Duration of Treatment. OncoTargets and Therapy, 6, 1011-1023.

[94]   NCCN Clinical Practice Guideline in Oncology.

[95]   ESMO/European Sarcoma Network Working Group (2012) Gastrointestinal Stromal Tumors: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 23, Vii49-Vii55.

[96]   Conley, A.P., Araujo, D., Ludwig, J., Ravi, V., Samuels, B.L., Choi, H., et al. (2009) A Randomized Phase II Study of Perifosine (P) plus Imatinib for Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST). Journal of Clinical Oncology, 27, 10563.

[97]   Schoffski, P., Reichardt, P., Blay, J.Y., Dumez, H., Morgan, J.A., Ray-Coquard, I., Hollaender, N., Jappe, A. and Demetri, G.D. (2010) A Phase I-II Study of Everolimus (RAD001) in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors. Annals of Oncology, 21, 1990-1998. http://dx.doi.org/10.1093/annonc/mdq076

[98]   Demetri, G.D., Le-Cesne, A., Von Mehren, M., et al. (2010) Final Results Form a Phase III Study of IPI-504 (Retaspimycin Hydrochloride) versus Placebo in Patients (Pts) with Gastrointestinal Stromal Tumors (GIST) Following Failure of Kinase Inhibitor Therapies. The ASCO Gastrointestinal Cancers Symposium, Orlando, 22-24 January 2010.

[99]   Vanel, D., Albiter, M., Shapeero, L., et al. (2005) Role of Computed Tomography in the Follow-Up of Hepatic and Peritoneal Metastases of GIST under Imatinib Mesylate Treatment: A Prospective Study of 54 Patients. European Journal of Radiology, 54, 118-123.

[100]   Choi, H., Charnsangavej, C., Faria, S.C., Macapinlac, H.A., Burgess, M.A., Patel, S.R., Chen, L.L., Podoloff, D.A. and Benjamin, R.S. (2007) Correlation of Computed Tomography and Positron Emission Tomography in Patients with Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution with Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria. Journal of Clinical Oncology, 25, 1753-1759. http://dx.doi.org/10.1200/JCO.2006.07.3049

[101]   Zhao, X. and Yue, C. (2012) Gastrointestinal Stromal Tumor. Journal of Gastrointestinal Oncology, 3, 189-208.

[102]   Láng, I., Hitre, E., Horváth, Z. and Godény, M. (2003) Case 3. Resection of Originally Inoperable Liver Metastases of Gastrointestinal Stromal Tumor after Imatinib Mesylate Therapy. Journal of Clinical Oncology, 21, 3538-3540. http://dx.doi.org/10.1200/JCO.2003.03.176

[103]   Andtbacka, R.H., Ng, C.S., Scaife, C.L., Cormier, J.N., Hunt, K.K., Pisters, P.W.T., et al. (2007) Surgical Resection of Gastrointestinal Stromal Tumors after Treatment with Imatinib. Annals of Surgical Oncology, 14, 14-24. http://dx.doi.org/10.1245/s10434-006-9034-8

[104]   Katz, D., Segal, A., Alberton, Y., Jurim, O., Reissman, P., Catane, R. and Cherny, N.I. (2004) Neoadjuvant Imatinib for Unresectable Gastrointestinal Stromal Tumor. Anticancer Drugs, 15, 599-602. http://dx.doi.org/10.1097/01.cad.0000132236.38297.a7

[105]   Bonvalot, S., Eldweny, H., Péchoux, C.L., Vanel, D., Terrier, P., Cavalcanti, A., Robert, C., Lassau, N. and Le Cesne, A. (2006) Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era. Annals of Surgical Oncology, 13, 1596-1603. http://dx.doi.org/10.1245/s10434-006-9047-3

[106]   Raut, C.P., Posner, M., Desai, J., Morgan, J.A., George, S., Zahrieh, D., Fletcher, C.D.M., Demetri, G.D. and Bertagnolli, M.M. (2006) Surgical Management of Advanced Gastrointestinal Stromal Tumors after Treatment with Targeted Systemic Therapy Using Kinase Inhibitors. Journal of Clinical Oncology, 24, 2325-2331. http://dx.doi.org/10.1200/JCO.2005.05.3439

[107]   Wang, D., Zhang, Q., Blanke, C.D., et al. (2012) Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumors: Long-Term Follow-Up Results of Radiation Therapy Oncology Group 0132. Annals of Surgical Oncology, 19, 1074-1080. http://dx.doi.org/10.1245/s10434-011-2190-5

[108]   Mcauliffe, J.C., Hunt, K.K., Lazar, A.J., Choi, H., Qiao, W., Thall, P., Pollock, R.E., Benjamin, R.S. and Trent, J.C. (2009) A Randomized, Phase II Study of Preoperative Plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis. Annals of Surgical Oncology, 16, 910-919. http://dx.doi.org/10.1245/s10434-008-0177-7

[109]   Dematteo, R.P., Ballman, K.V., Antonescu, C.R., et al. (2013) Long-Term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor: ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial. Annals of Surgery, 258, 422-429.

[110]   Dematteo, R.P., Ballman, K.V., Antonescu, C.R., et al. on Behalf of the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team (2009) Adjuvant Imatinib Mesylate after Resection of Localised, Primary Gastrointestinal Stromal Tumour: A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 373, 1097-1104.

[111]   Joensuu, H., Eriksson, M., Sundby Hall, K., et al. (2012) One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial. JAMA, 307, 1265-1272.

[112]   Casali, P., Le Cesne, A., Velasco, A.P., et al. (2013) Imatinib Failure-Free Survival (IFS) in Patients with Localized Gastrointestinal Stromal Tumors (GIST) Treated with Adjuvant Imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG Randomized Controlled Phase III Trial (Abstract). Journal of Clinical Oncology, 31.

[113]   Canazi, F.C.M., Judson, I., Lorenzi, B., Benson, C. and Mudan, S. (2013) Multidisciplinary Care of Gastrointestinal Stromal Tumour: A Review and a Proposal for a Pre-Treatment Classification. European Journal of Surgical Oncology, 39, 1171-1178. http://dx.doi.org/10.1016/j.ejso.2013.08.030

[114]   Weisberg, E., Wright, R.D., Jiang, J., Ray, A., Moreno, D., Manley, P.W., et al. (2006) Effects of PKC412, Nilotinib, and Imatinib against GIST-Associated PDGFRA Mutants with Differential Imatinib Sensitivity. Gastroenterology, 131, 1734-1742. http://dx.doi.org/10.1053/j.gastro.2006.09.017

[115]   Emile, J.F., Brahimi, S., Coindre, J.M., Bringuier, P.P., Monges, G., Samb, P., et al. (2012) Frequencies of KIT and PDGFRA Mutations in the Molecgist Prospective Population-Based Study Differ from Those of Advanced Gists. Medical Oncology, 29, 1765-1772. http://dx.doi.org/10.1007/s12032-011-0074-y

[116]   Debiec-Rychter, M., Sciot, R., Le Cesne, A., et al. on Behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, and the Australasian Gastrointestinal Trials Group (2006) KIT Mutations and Dose Selection for Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours. European Journal of Cancer, 42, 1093-1103. http://dx.doi.org/10.1016/j.ejca.2006.01.030

[117]   Brigden, M. and Ahmed, S. (2010) Literature-Based Follow-Up Recommendations for Solid Tumors (Part II). Oncology Exchange, 9, 11-16.

[118]   Plumb, A.A., Kochhar, R., Leahy, M. and Taylor, M.B. (2013) Patterns of Recurrence in Gastrointestinal Stromal Tumour (GIST) Following Complete Resection: Implications for Follow-Up. Clinical Radiology, 68, 770-775. http://dx.doi.org/10.1016/j.crad.2013.03.002

[119]   Yang, F., Jin, C., Du, Z., Subedi, S., Jiang, Y., Li, J., Di, Y., Zhou, Z.W., Tang, F. and Fu, D.L. (2013) Duodenal Gastrointestinal Stromal Tumor: Clinicopathological Characteristics, Surgical Outcomes, Long Term Survival and Predictors for Adverse Outcomes. American Journal of Surgery, 206, 360-367. http://dx.doi.org/10.1016/j.amjsurg.2012.11.010

[120]   Raval, P., Unadkat, S. and Kirthi, V. (2013) Rare and Unusual Metastases of A Gastrointestinal Stromal Tumour. Journal of Pakistan Medical Association, 63, 148-149.

[121]   Bamboat, Z.M. and Dematteo, R.P. (2014) Metastasectomy for Gastrointestinal Stromal Tumors. Journal of Surgical Oncology, 109, 23-27. http://dx.doi.org/10.1002/jso.23451

[122]   Cananzi, F.C.M., Belgaumkar, A.P., Lorenzi, B. and Mudan, S. (2013) Liver Surgery in the Multidisciplinary Management of Gastrointestinal Stromal Tumour. ANZ Journal of Surgery, 2013, 1-8.

[123]   Cheung, T.T., Chok, K.S.H., Chan, A.C.Y., Yau, T.C.C., Chan, S.C., Poon, R.T.P., Fan, S.T. and Lo, C.M. (2013) Analysis of Long-Term Survival after Hepatectomy for Isolated Liver Metastasis of Gastrointestinal Stromal Tumour. ANZ Journal of Surgery. http://dx.doi.org/10.1111/ans.12249

[124]   Gramza, A.W., Corless, C.L. and Heinrich, M.C. (2009) Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 15, 7510-7518.

[125]   Heinrich, M.C., Corless, C.L., Blanke, C.D., Demetri, G.D., Joensuu, H., Roberts, P.J., et al. (2006) Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 24, 4764-4774. http://dx.doi.org/10.1200/JCO.2006.06.2265

[126]   Yachoui, R. (2013) Early Onset Imatinib Mesylate-Induced Hepatotoxicity in a Patient with Gastrointestinal Stromal Tumors. American Journal of Therapeutics.

[127]   Demetri, G.D., Van Oosterom, A.T., Garrett, C.R., Blackstein, M.E., Shah, M.H., Verweij, J., et al. (2006) Efficacy and Safety of Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumour after Failure of Imatinib: A Randomized Controlled Trial. The Lancet, 368, 1329-1338.

[128]   Demetri, G.D., Garrett, C.R., Sch?ffski, P., Shah, M.H., Verweij, J., Leyvraz, S., et al. (2012) Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor Following Imatinib Failure. Clinical Cancer Research, 18, 3170. http://dx.doi.org/10.1158/1078-0432.CCR-11-3005

[129]   Demetri, G.D., Heinrich, M.C., Fletcher, J.A., et al. (2009) Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure. Clinical Cancer Research, 15, 5902. http://dx.doi.org/10.1158/1078-0432.CCR-09-0482

[130]   Heinrich, M.C., Maki, R.G., Corless, C.L., Antonescu, C.R., Harlow, A., Griffith, D., et al. (2008) Primary and Secondary Kinase Genotypes Correlate with the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 26, 5352-5359. http://dx.doi.org/10.1200/JCO.2007.15.7461

[131]   Rutkowski, P., Bylina, E., Klimczak, A., ?witaj, T., Falkowski, S., Kroc, J., et al. (2012) The Outcome and Predictive Factors of Sunitinib Therapy in Advanced Gastrointestinal Stromal Tumors (GIST) after Imatinib Failure—One Institution Study. BMC Cancer, 12, 107. http://dx.doi.org/10.1186/1471-2407-12-107

[132]   George, S., Wang, Q., Heinrich, M.C., Corless, C.L., Zhu, M.J., Butrynski, J.E., et al. (2012) Efficacy and Safety of Regorafenib in Patients with Metastatic and/or Unresectable GI Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial. Journal of Clinical Oncology, 30, 2401-2407. http://dx.doi.org/10.1200/JCO.2011.39.9394

[133]   Demetri, G.D., Reichardt, P., Kang, Y.K., Blay, J.Y., Rutkowski, P., Gelderblom, H., et al. (2013) Efficacy and Safety of Regorafenib for Advanced Gastrointestinal Stromal Tumours after Failure of Imatinib and Sunitinib (GRID): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, 381, 295-302. http://dx.doi.org/10.1016/S0140-6736(12)61857-1

[134]   Montemurro, M., Schoffski, P., Reichardt, P., Gelderblom, H., Schütte, J., Hartmann, J.T., et al. (2009) Nilotinib in the Treatment of Advanced Gastrointestinal Stromal Tumours Resistant to Both Imatinib and Sunitinib. European Journal of Cancer, 45, 2293-2297.

[135]   Sawaki, A., Nishida, T., Doi, T., Yamada, Y., Komatsu, Y., Kanda, T., Kakeji, Y., Onozawa, Y., Yamasaki, M. and Ohtsu, A. (2011) Phase 2 Study of Nilotinib as Third-Line Therapy for Patients with Gastrointestinal Stromal Tumor. Cancer, 117, 4633-4641. http://dx.doi.org/10.1002/cncr.26120

[136]   Cauchi, C., Somaiah, N., Engstrom, P.F., Litwin, S., Lopez, M., Lee, J., Davey, M., Bove, B. and von Mehren, M. (2012) Evaluation of Nilotinib in Advanced GIST Previously Treated with Imatinib and Sunitinib. Cancer Chemotherapy and Pharmacology, 69, 977-982. http://dx.doi.org/10.1007/s00280-011-1785-7

[137]   Reichardt, P., Blay, J.Y., Gelderblom, H., Schlemmer, M., Demetri, G.D., Bui-Nguyen, B., et al. (2012) Phase III Study of Nilotinib versus Best Supportive Care with or without a TKI in Patients with Gastrointestinal Stromal Tumors Resistant to or Intolerant of Imatinib and Sunitinib. Annals of Oncology, 23, 1680-1687. http://dx.doi.org/10.1093/annonc/mdr598

[138]   Campbell, N.P., Wroblewski, K., Maki, R.G., et al. (2011) Final Results of a University of Chicago Phase II Consortium Trial of Sorafenib (SOR) in Patients (Pts) with Imatinib (IM)- and Sunitinib (SU)-Resistant (RES) Gastrointestinal Stromal Tumors (GIST). Journal of Clinical Oncology, 29.

[139]   Park, S.H., Ryu, M.H., Ryoo, B.Y., Im, S.A., Kwon, H.C., Lee, S.S., Park, S.R., Kang, B.Y. and Kang, Y.K. (2012) Sorafenib in Patients with Metastatic Gastrointestinal Stromal Tumors Who Failed Two or More Prior Tyrosine Kinase Inhibitors: A Phase II Study of Korean Gastrointestinal Stromal Tumors Study Group. Investigational New Drugs, 30, 2377-2383. http://dx.doi.org/10.1007/s10637-012-9795-9

[140]   Montemurro, M., Gelderblom, H., Bitz, U., Schütte, J., Blay, J.Y., Joensuu, H., Trent, J., Bauer, S., Rutkowski, P., Duffaud, F. and Pink, D. (2013) Sorafenib as Third- or Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumour and Pretreatment Including both Imatinib and Sunitinib, and Nilotinib: A Retrospective Analysis. European Journal of Cancer, 49, 1027-1031.

[141]   Benjamin, R.S., Sch?ffski, P., Hartmann, J.T., Van Oosterom, A., Bui, B.N., Duyster, J., et al. (2011) Efficacy and Safety of Motesanib, an Oral Inhibitor of VEGF, PDGF, and Kit Receptors, in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors. Cancer Chemotherapy and Pharmacology, 68, 69-77. http://dx.doi.org/10.1007/s00280-010-1431-9

[142]   Dewaele, B., Wasag, B., Cools, J., Sciot, R., Prenen, H., Vandenberghe, P., Wozniak, A., Sch?ffski, P., Marynen, P. and Debiec-Rychter, M. (2008) Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation. Clinical Cancer Research, 14, 5749-5758. http://dx.doi.org/10.1158/1078-0432.CCR-08-0533

[143]   Joensuu, H., De Braud, F., Grignagni, G., De Pas, T., Spitalieri, G., Coco, P., et al. (2011) Vatalanib for Metastatic Gastrointestinal Stromal Tumour (GIST) Resistant to Imatinib: Final Results of a Phase II Study. British Journal of Cancer, 104, 1686-1690. http://dx.doi.org/10.1038/bjc.2011.151

[144]   Serrano, C. and George, S. (2014) Recent Advances in the Treatment of Gastrointestinal Stromal Tumors. Therapeutic Advances in Medical Oncology, 6, 115-127.

[145]   Demir, L., Ekinci, N., Erten, C., Kucukzeybek, Y., Alacacioglu, A., Somali, I., et al. (2013) Does Immunohistochemistry Provide Additional Prognostic Data in Gastrointestinal Stromal Tumors? Asian Pacific Journal of Cancer Prevention, 14, 4751-4758.

[146]   Yang, H., Shen, C., Zhang, B., Chen, H., Chen, Z. and Chen, J. (2013) Expression and Clinicopathological Significance of CD9 in Gastrointestinal Stromal Tumor. Journal of Korean Medical Science, 28, 1443-1448. http://dx.doi.org/10.3346/jkms.2013.28.10.1443

[147]   Kubota, D., Yoshida, A., Tsuda, H., Suehara, Y., Okubo, T., Saito, T., et al. (2013) Gene Expression Network Analysis of ETV1 Reveals KCTD10 as a Novel Prognostic Biomarker in Gastrointestinal Stromal Tumor. PLoS ONE, 19, Article ID: e73896. http://dx.doi.org/10.1371/journal.pone.0073896